DexCom (NASDAQ:DXCM) Director Bridgette Heller Sells 1,012 Shares

DexCom, Inc. (NASDAQ:DXCM) Director Bridgette Heller sold 1,012 shares of DexCom stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares of the company’s stock, valued at $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

DexCom Trading Up 0.8%

DexCom stock traded up $0.47 during midday trading on Thursday, reaching $60.08. 1,125,374 shares of the stock traded hands, compared to its average volume of 4,549,601. The firm has a market cap of $23.43 billion, a PE ratio of 41.74, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The company has a 50-day simple moving average of $68.12 and a two-hundred day simple moving average of $77.39. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.04. The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business’s quarterly revenue was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.45 earnings per share. DexCom has set its FY 2025 guidance at EPS. Research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on DXCM. TD Cowen dropped their price target on shares of DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research note on Friday, October 31st. Weiss Ratings reiterated a “hold (c-)” rating on shares of DexCom in a report on Wednesday, October 8th. Mizuho upped their price target on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Wells Fargo & Company set a $93.00 price target on DexCom and gave the company an “overweight” rating in a research report on Friday, October 31st. Finally, Canaccord Genuity Group set a $99.00 price objective on DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $87.62.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of DXCM. Brighton Jones LLC raised its stake in DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after acquiring an additional 11,946 shares during the last quarter. Stratos Wealth Partners LTD. lifted its holdings in shares of DexCom by 32.7% during the first quarter. Stratos Wealth Partners LTD. now owns 3,428 shares of the medical device company’s stock worth $234,000 after purchasing an additional 845 shares during the period. Allworth Financial LP grew its position in DexCom by 163.3% in the 1st quarter. Allworth Financial LP now owns 2,846 shares of the medical device company’s stock valued at $201,000 after buying an additional 1,765 shares during the last quarter. Cerity Partners LLC raised its position in DexCom by 4.1% during the 1st quarter. Cerity Partners LLC now owns 69,601 shares of the medical device company’s stock worth $4,753,000 after buying an additional 2,711 shares during the last quarter. Finally, CWM LLC lifted its stake in shares of DexCom by 2.4% in the 1st quarter. CWM LLC now owns 166,144 shares of the medical device company’s stock worth $11,346,000 after acquiring an additional 3,897 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.